Patents by Inventor Edward Otto
Edward Otto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9388959Abstract: A white-light emitter is disclosed, in which a silicone sheet is laminated between a pair of optically clear plastic sheets. The silicone sheet lacks the ability to retain its shape, while the three sheets, when sealed together, can retain a shape. The silicone sheet includes at least one phosphor, with a phosphor concentration between two percent and ten percent. The silicone sheet may be produced by molding. Compared to comparable silicone parts made by extrusion, the molded parts may show less part-to-part variation in color temperature, may be run in significantly smaller batches or as one-offs, and may allow the silicone and phosphor material to be mixed by hand or with a relatively simple mixing machine. In some cases, the sheets are sealed together at their perimeters and include a margin around the phosphor sheet. In some cases, the phosphor sheet includes a mixture of different phosphors.Type: GrantFiled: March 2, 2012Date of Patent: July 12, 2016Assignee: OSRAM SYLVANIA Inc.Inventors: Jason Lessard, Edward Otto
-
Patent number: 8883753Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analog of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analog of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.Type: GrantFiled: June 22, 2011Date of Patent: November 11, 2014Assignee: Virxsys CorporationInventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
-
Patent number: 8591076Abstract: A white-light emitter is disclosed, in which light from blue light-emitting diodes strikes an active area of a phosphor sheet. The active area absorbs a portion of the blue light and emits phosphor light in response to the absorbed blue light. The emitter includes a stretcher that controllably stretches the active area of the phosphor sheet. The white light output spectrum of the active area has a characteristic color temperature that increases as the phosphor sheet is stretched, and decreases as the phosphor sheet contracts. As the phosphor sheet is stretched, the thickness of the active area decreases, the received blue light encounters fewer phosphor particles within the active area, the absorbed portion of the blue light decreases, the emitted phosphor light decreases, and the active area has a white light output spectrum that becomes weighted more heavily toward the blue light and less heavily toward the phosphor light.Type: GrantFiled: March 2, 2012Date of Patent: November 26, 2013Assignee: Osram Sylvania Inc.Inventors: Jason Lessard, Edward Otto
-
Publication number: 20130228800Abstract: A white-light emitter is disclosed, in which a silicone sheet is laminated between a pair of optically clear plastic sheets. The silicone sheet lacks the ability to retain its shape, while the three sheets, when sealed together, can retain a shape. The silicone sheet includes at least one phosphor, with a phosphor concentration between two percent and ten percent. The silicone sheet may be produced by molding. Compared to comparable silicone parts made by extrusion, the molded parts may show less part-to-part variation in color temperature, may be run in significantly smaller batches or as one-offs, and may allow the silicone and phosphor material to be mixed by hand or with a relatively simple mixing machine. In some cases, the sheets are sealed together at their perimeters and include a margin around the phosphor sheet. In some cases, the phosphor sheet includes a mixture of different phosphors.Type: ApplicationFiled: March 2, 2012Publication date: September 5, 2013Applicant: OSRAM SYLVANIA INC.Inventors: Jason Lessard, Edward Otto
-
Publication number: 20130229784Abstract: A white-light emitter is disclosed, in which light from blue light-emitting diodes strikes an active area of a phosphor sheet. The active area absorbs a portion of the blue light and emits phosphor light in response to the absorbed blue light. The emitter includes a stretcher that controllably stretches the active area of the phosphor sheet. The white light output spectrum of the active area has a characteristic color temperature that increases as the phosphor sheet is stretched, and decreases as the phosphor sheet contracts. As the phosphor sheet is stretched, the thickness of the active area decreases, the received blue light encounters fewer phosphor particles within the active area, the absorbed portion of the blue light decreases, the emitted phosphor light decreases, and the active area has a white light output spectrum that becomes weighted more heavily toward the blue light and less heavily toward the phosphor light.Type: ApplicationFiled: March 2, 2012Publication date: September 5, 2013Applicant: OSRAM SYLVANIA INC.Inventors: Jason Lessard, Edward Otto
-
Patent number: 8357469Abstract: A bipolar battery construction is disclosed comprising a substrate, openings in the substrate, an electrically conductive material placed within the openings, a negative and positive current collector foil placed on opposing sides of the substrate and negative and positive pasting frame members. The electrically conductive material may have a melting point below the thermal degradation temperature of the substrate.Type: GrantFiled: January 20, 2010Date of Patent: January 22, 2013Assignee: Advanced Battery Concepts, LLCInventors: Edward Otto Shaffer, II, William Buttfield Brecht
-
Publication number: 20120046347Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.Type: ApplicationFiled: June 22, 2011Publication date: February 23, 2012Applicant: Virxsys CorporationInventors: Madaiah Pattaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
-
Patent number: 8053232Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells.Type: GrantFiled: January 21, 2005Date of Patent: November 8, 2011Assignee: VIRxSYS CorporationInventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple, Lloyd G. Mitchell, Colette Cote, S. Gary Mansfield
-
Patent number: 7968334Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.Type: GrantFiled: May 31, 2005Date of Patent: June 28, 2011Assignee: VIRxSYS CorporationInventors: Madaiah Puttaraju, Edward Otto, Mariano A. Garcia-Blanco, Gerard J. McGarrity, Gary F. Temple
-
Publication number: 20100183920Abstract: A bipolar battery construction is disclosed comprising a substrate, openings in the substrate, an electrically conductive material placed within the openings, a negative and positive current collector foil placed on opposing sides of the substrate and negative and positive pasting frame members. The electrically conductive material may have a melting point below the thermal degradation temperature of the substrate.Type: ApplicationFiled: January 20, 2010Publication date: July 22, 2010Applicant: Advanced Battery Concepts, LLCInventors: Edward Otto Shaffer, II, William Buttfield Brecht
-
Publication number: 20090203143Abstract: The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.Type: ApplicationFiled: June 9, 2008Publication date: August 13, 2009Applicant: VIRXSYS CORPORATIONInventors: Lloyd G. Mitchell, Edward Otto, Carl R. Merril
-
Patent number: 7468479Abstract: The proposed solution to problems associated with pad leveling and effective tone hole closure, employs a pad with a beveled backer that is relatively rigid, and an adjoining contact layer that seals a corresponding tone hole when a musical instrument key is actuated. In one embodiment, the backer features a sloping side wall, and optionally a side wall portion having a curved contour. Leveling of the pad is accomplished by placing the backer partially within a pad cup, adjusting the pad orientation while maintaining sliding contact between the backer and the pad cup, and fixing the pad within the pad cup. The backer is preferably shaped to provide support to all portions of the contact layer. Another embodiment features a step-bevel backer that is sized to fit a pad cup, and preferably supports all portions of an adjoining contact layer whose diameter exceeds that of the pad cup.Type: GrantFiled: April 21, 2005Date of Patent: December 23, 2008Inventor: Edward Otto Kraus
-
Publication number: 20080181531Abstract: A method is provided for emboldening a bitmap character, which includes using a bitmap for a character to be emboldened and selectively turning on pixels of the bitmap of the character, which are initially off, based on whether the pixels are immediately adjacent to an initially off pixel. The bitmap character to be emboldened can either be an embedded font character or the character can be generated from a glyph stroke or outline which is scaled to a desired size. The method is applied to all base pixels which form the character until the entire character is emboldened.Type: ApplicationFiled: January 25, 2007Publication date: July 31, 2008Applicant: Monotype Imaging Inc.Inventor: Edward Otto Platz
-
Patent number: 7399753Abstract: The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.Type: GrantFiled: September 9, 2003Date of Patent: July 15, 2008Assignee: Virxsys CorporationInventors: Lloyd G. Mitchell, Edward Otto, Carl R. Merril
-
Patent number: 7232126Abstract: The present subject matter relates to the field of document material handling in high-speed in-line mailing systems. In particular, the present subject matter relates to a cross track divert device, system and method for diverting a suspect or invalid document from a paper pathway prior to the document entering a raceway conveyor. The cross track divert device is designed to divert and remove the suspect or invalid document without stoppage of the mailing system's operation cycle.Type: GrantFiled: December 29, 2004Date of Patent: June 19, 2007Assignee: Bowe Bell + Howell CompanyInventors: Michael Drago, Edward Otto
-
Publication number: 20060234247Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells.Type: ApplicationFiled: January 21, 2005Publication date: October 19, 2006Inventors: Madaiah Puttaraju, Edward Otto, Mariano Garcia-Blanco, Gerard McGarrity, Gary Temple, Lloyd Mitchell, Colette Cote, S. Mansfield
-
Publication number: 20060194317Abstract: Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i.e., atherosclerosis, strokes and heart attacks.Type: ApplicationFiled: May 31, 2005Publication date: August 31, 2006Inventors: Madaiah Puttaraju, Edward Otto, Mariano Garcia-Blanco, Gerard McGarrity, Gary Temple
-
Patent number: 7094399Abstract: The present invention provides methods and compositions for conferring tumor selective cell death on cancer cells expressing specific target precursor messenger RNA molecules (cancer cell selective target pre-mRNAs). The compositions of the invention include conditionally replicative adenoviruses that have been genetically engineered to express one or more pre-trans-splicing molecules (PTMs) designed to interact with one or more cancer cell target pre-mRNA and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecules (chimeric RNA) capable of encoding adenovirus specific protein(s). Adenovirus specific proteins include those proteins complementing an essential activity necessary for replication of a defective adenovirus. The methods and compositions of the invention may be used to target a lytic adenovirus infection to cancer cells thereby providing a method for selective destruction of cancer cells.Type: GrantFiled: May 8, 2003Date of Patent: August 22, 2006Assignee: Intronn, Inc.Inventor: Edward Otto
-
Publication number: 20060177933Abstract: The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of an apoA-1 variant, the preferred embodiment referred to herein as the apoA-1 Milano variant. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding the apoA-1 Milano variant. The expression of this variant protein results in protection against vascular disorders resulting from plaque build up, i.e., strokes and heart attacks. In particular, the PTMs of the present invention include those genetically engineered to interact with the apoA-1 target pre-mRNA so as to result in expression of the apoA-1 Milano variant.Type: ApplicationFiled: January 21, 2005Publication date: August 10, 2006Inventors: Madaiah Puttaraju, Edward Otto, Mariano Garcia-Blanco, Gerard McGarrity, Gary Temple
-
Publication number: 20060157925Abstract: The present subject matter relates to the filed of document material handling in high-speed in-line mailing systems. In particular, the present subject matter relates to a cross track divert device, system and method for diverting a suspect or invalid document from a paper pathway prior to the document entering a raceway conveyor. The cross track divert device is designed to divert and remove the suspect or invalid document without stoppage of the mailing system's operation cycle.Type: ApplicationFiled: December 29, 2004Publication date: July 20, 2006Inventors: Michael Drago, Edward Otto